Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Large trade out the gate:
06/16/2023 9:30:01 EDT X 17.14 105212
Nice! Thanks for posting.
Wow! Much earlier than usual.
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2023 After Market Close on June 21, 2023
June 14, 2023 at 4:05 PM EDT
Download PDF
TUSTIN, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year ended April 30, 2023 on June 21, 2023, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the quarter and fiscal year ended April 30, 2023, and review recent corporate developments.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.
About Avid Bioservices, Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 30 years of experience producing biologics, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Like clockwork.
https://ir.avidbio.com/node/20131/html
Jun 5 - 8
2023
Boston Convention & Exhibition Center, Boston, MA
About the Conference
Over 14,000+ Biotechnology and Pharma Leaders Attending with Extensive Networking Opportunities.
Meet the team at Booth # 1765
Join us at the BPI Theater:
Rountable Discussion with Rich Richieri, Chief Operations Officer
Monday, June 5th at 2:15 – 3:00pm ET
Topic of discussion: How did the pandemic adjust the CDMO landscape and how will the sector change moving forward?
Presentation by Chris Berger, Executive Director of Quality – Viral Vector Technologies
Tuesday, June 6th at 11:20am ET
Build it Right: A Quality Perspective on the Design and Buid of a Viral Vector CDMO Manufacturing Facility
Presentation by Pramthesh Patel, Vice President of Process Development
Wednesday, June 7th at 11:20am ET
The Importance of the Approaches, Philosophy, and Constraints to Process Characterization at a CDMO
Thanks for the insight.
Avid Bioservices Inc. (CDMO)
Pre-Market: $17.23 0.82 | 5.00%07:17 AMEDTVolume: 1
Nice action today but no volume to back it up.
Someone seems intent on bringing this down at little cost this morning.
05/30/2023 7:32:17 EDT I 14.501 10 NDD
05/30/2023 7:07:15 EDT I 14.75 99 CBOE EDGX
05/30/2023 7:07:15 EDT I 14.74 1 CBOE
Premarket of no value whatsoever, but I like the price.
05/26/2023 8:37:08 EDT I 15.97 1 NDD
Also, the ask is .05 and the trades were at .24-.25.
195 May 2.50 puts sold today. They expire today. There was no prior volume to offset it. Someone please explain the purpose of this trade to me.
Final buy/sell volume today: 480K/272K.
I’m glad the gap filled. It may take a few days but I expect this to move up substantially. I bought a load more.
On twitter Laughing Water Capital said an RBC analyst said Cdmo revenues are lumpy businesses. With capacity about to double and capacity prebooked they aren’t concerned about Avid.
Filings so far today
Date Source Investor Type Avg Price
(Est) Shares ? Shares
(%) Reported
Value
($1000) ? Value
(%) Port Alloc
(%)
2023-05-18 13F/A Jpmorgan Chase & Co 78,157 11.51 1,466
2023-05-18 NP MUTUAL OF AMERICA INVESTMENT CORP - Small Cap Equity Index Fund Class 12,355 -1.47 232 34.30
2023-05-18 13F/A New York State Common Retirement Fund 841,286 7.59 16 50.00
2023-05-18 NP Mutual of America Variable Insurance Portfolios, Inc. - Small Cap Equity Index Portfolio Class 477 -2.45
Buy vol 214K sell 185K
I saw someone bought 300 yesterday.
Just fill the gap so we can move on.
Buy volume 561K sell volume 433K. In between 177K.
Still, the volume isn’t extraordinary. I’ve bought more three times today. As Stoneroad said, there is still a downward gap. Unless there was an earthquake we didn’t hear about, I can’t see a valid reason for this drop.
NASDAQ still shows 103.67% institutional ownership.
Buy volume 156K sell volume 146K.
https://ih.advfn.com/stock-market/NASDAQ/avid-bioservices-CDMO/trades?pid=trades&symbol=NASDAQ:CDMO
I don’t understand the comment on reduction in revenues:
Threat
Debt is not well covered by operating cash flow.
Annual earnings are forecast to decline for the next 3 years.
Is CDMO well equipped to handle threats?
Institutional investment up to 121% from 119% a couple of days ago.
Institutional Shares (Long) 75,691,136 - 121.01% (ex 13D/G) - change of shares - change of % MR
Avid Bioservices to Participate in RBC Capital Markets Global Healthcare Conference
May 10, 2023 at 4:05 PM EDT
Download PDF
TUSTIN, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the RBC Capital Markets Global Healthcare Conference. Nick Green, president and chief executive officer, will be the featured speaker in a fireside chat at the conference, which will take place May 16-17, 2023.
Details of the company’s participation are as follows:
RBC Capital Markets Global Healthcare Conference
Conference Date: May 16-17, 2023
Fireside Chat Time/Date: 8:30 - 8:55 a.m. Eastern on Wednesday, May 17, 2023
About?Avid Bioservices, Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 30 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Primary Logo
Source: Avid Bioservices, Inc
So what’s up with the 220 shares at 19.25 premarket? Unfortunately the ask is 18.75 now.
Any idea on why HALO has been so beaten up?
For. 4’s filed for Hancock and Zeibell. Sold all they vested.
Note this is the only board he/she posts on, unless other aliases are used.
Also one for 87K just after the close
Date/Time Price Shares Exch/Mkt
04/25/2023 18:10:57 EDT I 18.60 25 ARCA
04/25/2023 17:27:12 EDT P 18.57 79000 NDD
04/25/2023 17:20:06 EDT I 18.69 4 NSD
04/25/2023 16:01:12 EDT P 18.57 2381 NDD
04/25/2023 16:01:10 EDT P 18.57 476 NDD
04/25/2023 16:01:08 EDT P 18.57 270 NDD
04/25/2023 16:01:04 EDT P 18.57 419 NDD
04/25/2023 16:00:15 EDT I 18.57 9 NDD
04/25/2023 16:00:15 EDT P 18.57 1595 NDD
04/25/2023 16:00:15 EDT I 18.57 32 NDD
04/25/2023 16:00:15 EDT P 18.57 6609 NDD
04/25/2023 16:00:15 EDT I 18.57 96 NDD
04/25/2023 16:00:06 EDT W 18.57 87000
FWIW, today is options expiration.
Higher than normal AH action today.
17/2023 17:26:15 EDT P 19.31 91600 NDD
04/17/2023 17:26:15 EDT P 19.31 56500 NDD
04/17/2023 16:23:34 EDT I 19.31 1 NSD
04/17/2023 16:08:25 EDT I 19.312 1 NDD
04/17/2023 16:01:10 EDT T 19.31 266 NDD
04/17/2023 16:00:39 EDT T 19.31 26786 NDD
04/17/2023 16:00:34 EDT T 19.31 145 NDD
04/17/2023 16:00:32 EDT T 19.31 130 NDD
04/17/2023 16:00:32 EDT I 19.31 56 NDD
04/17/2023 16:00:05 EDT T 19.31 923 NDD
04/17/2023 16:00:05 EDT T 19.31 4828 NDD
04/17/2023 16:00:01 EDT T 19.31 483 NDD
04/17/2023 16:00:01 EDT T 19.31 202
Your last post was on 4/4 when CDMO closed at 18.85. It’s 80 cents higher than that closing today in spite of being down 1.27 on the day. Your taunts are rather pathetic.
CTLT down 27%. Wow!
Agreed. I bought more trading shares at 19.60. Hoping it doesn’t go much lower.
What the H*** is a Form 144
https://ir.avidbio.com/node/20086/html
Rule 144: Selling Restricted and Control Securities
Jan. 16, 2013
When you acquire restricted securities or hold control securities, you must find an exemption from the SEC's registration requirements to sell them in a public marketplace. Rule 144 allows public resale of restricted and control securities if a number of conditions are met. This overview tells you what you need to know about selling your restricted or control securities. It also describes how to have a restrictive legend removed.
What Are Restricted and Control Securities?
Restricted securities are securities acquired in unregistered, private sales from the issuing company or from an affiliate of the issuer. Investors typically receive restricted securities through private placement offerings, Regulation D offerings, employee stock benefit plans, as compensation for professional services, or in exchange for providing "seed money" or start-up capital to the company. Rule 144(a)(3) identifies what sales produce restricted securities.
Control securities are those held by an affiliate of the issuing company. An affiliate is a person, such as an executive officer, a director or large shareholder, in a relationship of control with the issuer. Control means the power to direct the management and policies of the company in question, whether through the ownership of voting securities, by contract, or otherwise. If you buy securities from a controlling person or "affiliate," you take restricted securities, even if they were not restricted in the affiliate's hands.
If you acquire restrictive securities, you almost always will receive a certificate stamped with a "restrictive" legend. The legend indicates that the securities may not be resold in the marketplace unless they are registered with the SEC or are exempt from the registration requirements. Certificates for control securities usually are not stamped with a legend.
What Are the Conditions of Rule 144?
If you want to sell your restricted or control securities to the public, you can meet the applicable conditions set forth in Rule 144. The rule is not the exclusive means for selling restricted or control securities, but provides a "safe harbor" exemption to sellers. The rule's five conditions are summarized below:
Additional securities purchased from the issuer do not affect the holding period of previously purchased securities of the same class. If you purchased restricted securities from another non-affiliate, you can tack on that non-affiliate's holding period to your holding period. For gifts made by an affiliate, the holding period begins when the affiliate acquired the securities and not on the date of the gift. In the case of a stock option, including employee stock options, the holding period begins on the date the option is exercised and not the date it is granted.
Holding Period. Before you may sell any restricted securities in the marketplace, you must hold them for a certain period of time. If the company that issued the securities is a “reporting company” in that it is subject to the reporting requirements of the Securities Exchange Act of 1934, then you must hold the securities for at least six months. If the issuer of the securities is not subject to the reporting requirements, then you must hold the securities for at least one year. The relevant holding period begins when the securities were bought and fully paid for. The holding period only applies to restricted securities. Because securities acquired in the public market are not restricted, there is no holding period for an affiliate who purchases securities of the issuer in the marketplace. But the resale of an affiliate's shares as control securities is subject to the other conditions of the rule.
Current Public Information. There must be adequate current information about the issuing company publicly available before the sale can be made. For reporting companies, this generally means that the companies have complied with the periodic reporting requirements of the Securities Exchange Act of 1934. For non-reporting companies, this means that certain company information, including information regarding the nature of its business, the identity of its officers and directors, and its financial statements, is publicly available.
Trading Volume Formula. If you are an affiliate, the number of equity securities you may sell during any three-month period cannot exceed the greater of 1% of the outstanding shares of the same class being sold, or if the class is listed on a stock exchange, the greater of 1% or the average reported weekly trading volume during the four weeks preceding the filing of a notice of sale on Form 144. Over-the-counter stocks, including those quoted on the OTC Bulletin Board and the Pink Sheets, can only be sold using the 1% measurement.
Ordinary Brokerage Transactions. If you are an affiliate, the sales must be handled in all respects as routine trading transactions, and brokers may not receive more than a normal commission. Neither the seller nor the broker can solicit orders to buy the securities.
Filing a Notice of Proposed Sale With the SEC. If you are an affiliate, you must file a notice with the SEC on Form 144 if the sale involves more than 5,000 shares or the aggregate dollar amount is greater than $50,000 in any three-month period.
If I Am Not an Affiliate of the Issuer, What Conditions of Rule 144 Must I Comply With?
If you are not (and have not been for at least three months) an affiliate of the company issuing the securities and have held the restricted securities for at least one year, you can sell the securities without regard to the conditions in Rule 144 discussed above. If the issuer of the securities is subject to the Exchange Act reporting requirements and you have held the securities for at least six months but less than one year, you may sell the securities as long as you satisfy the current public information condition.
Can the Securities Be Sold Publicly If the Conditions of Rule 144 Have Been Met?
Even if you have met the conditions of Rule 144, you can't sell your restricted securities to the public until you've gotten the legend removed from the certificate. Only a transfer agent can remove a restrictive legend. But the transfer agent won't remove the legend unless you've obtained the consent of the issuer—usually in the form of an opinion letter from the issuer's counsel—that the restrictive legend can be removed. Unless this happens, the transfer agent doesn't have the authority to remove the legend and permit execution of the trade in the marketplace.
To begin the legend removal process, an investor should contact the company that issued the securities, or the transfer agent for the securities, to ask about the procedures for removing a legend. Removing the legend can be a complicated process requiring you to work with an attorney who specializes in securities law.
What If a Dispute Arises Over Whether I Can Remove the Legend?
If a dispute arises about whether a restrictive legend can be removed, the SEC will not intervene. Removal of a legend is a matter solely in the discretion of the issuer of the securities. State law, not federal law, covers disputes about the removal of legends. Thus, the SEC will not take action in any decision or dispute about removing a restrictive legend.
New 52 wk high.
My 18.25 buy Monday looks pretty good for now.
We hit it. Higher highs are good.